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INTRODUCTION
The human organism, constantly exposed to a large varie-
ty of pathogenic microorganisms and their products, such 
as endotoxin, has developed innate immunity as a fi rst line 
of defence. One of the compartments of our organism well 
equipped with these defence mechanisms is the respiratory 
system, being constantly exposed to airborne bacteria, fun-
gi, viruses and other pollutants including dusts and vola-
tile compounds. The respiratory epithelium is an important 
interface with the environment and represents a key system 
with regard to the innate host immunity of the lung. In ad-
dition to major immunoregulatory properties [15, 21], the 
cells lining the airways respond to the presence of virulent 
microorganisms by producing natural antimicrobial pep-
tides (AMPs). These factors play also numerous roles in 
many processes preserving homeostasis in the airways [4]. 
These antimicrobial peptides (AMPs) provide immediate 
protection against the invasion of a broad spectrum of mi-
croorganisms, including Gram-negative bacteria releasing 
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to the environment lipopolysaccharides (LPS) – heteropoly-
meric components of their outer layer membrane with 
strong immunotoxic properties.
ANTIMICROBIAL PEPTIDES – HUMAN 
CATHELICIDIN: PEPTIDE LL-37 
The fi rst descriptions of this group of peptides appeared 
in early 70s of the past century. During the last three deca-
des, hundreds of antimicrobial peptides have been discov-
ered, both in plants and animals. In humans, these peptides 
include members of three antimicrobial peptide families: 
defensins, histatins and cathelicidins [28]. Cathelicidins 
have been found in cows (BMAP-27, indolicidin, and 
bactenecin), pigs (protegrins), mice (CRAMP), rabbits 
(CAP18) [2]. This family of peptides derives from proteins 
that contain a highly conserved amino acid sequence and a 
proregion highly homologous to cathelin, a cathepsin L in-
hibitor. However, cathelicidins’ C-terminal domain shows 
substantial heterogeneity [28]. 
The only member of the cathelicidins family found to 
date in humans is LL-37/hCAP18, an 18 kDa peptide en-
coded by the gene CAMP, which was fi rst described in hu-
mans in 1995 in bone marrow cells. LL-37/hCAP18 is a 
small peptide of 37 amino acid residues starting with two 
leucine residues [23]. This peptide is derived by extracel-
lular proteolysis from the C-terminal end of the human 
CAP18 protein (hCAP18) [28]. LL-37 has been found 
in leukocytes and epithelial cells of the airways, but also 
within the gastrointestinal and urinary tracts and the skin. 
LL-37 is also likely to be involved in the pathogenesis of 
several diseases (e.g. morbus Kostmann, a severe congeni-
tal form of neutropenia, originally defi ned in descendants 
of the Kostmann family characterized by lacking antimi-
crobial peptide LL-37) [23]. LL-37 is a part of our immune 
system which is present in the human organism at a very 
early stage of development – the peptide has been found 
not only in newborns but even in amniotic fl uid [33]. The 
role of LL-37 has been also studied in pulmonary patholo-
gies – e.g. in sarcoidosis, where activation of antibacterial 
defence system has been suggested [1].
LL-37 is actively secreted into the airway surface fl uid 
layer where it can be found at concentrations of an aver-
age of about 2 μl/ml [3, 12, 20, 30] and exerts a broad 
antibacterial activity [28] typical for cathelicidins. LL-37 
performs its bactericidal action by electrostatic binding of 
its cationic molecules to the outer surface of the bacterial 
cell. Insertion of the peptide into the cell membrane re-
sults in leakage of the cell cytoplasm into the extracellular 
space causing death of the bacterial cell [28]. In addition 
to its bactericidal effect, LL-37 is able to neutralize LPS, 
and in doing so, protects against endotoxic shock [10, 28]. 
LL-37 binds to LPS, dissociates endotoxin aggregates and 
competes with LPS on the binding site within the CD14 
receptor, preventing endotoxin-dependent cytokine in-
duction and macrophage activation [24]. This activity has 
been confi rmed by both in in vitro [24] and in vivo studies 
[10]. In vitro studies also showed that LL-37 prevented the 
proinfl ammatory activation of monocytes due to LPS by 
suppressing Toll-like receptor (TLR)-induced secretion 
of proinfl ammatory cytokines [16]. In addition to its di-
rect antimicrobial and anti-LPS functions, LL-37 interacts 
also with human cells by the formyl peptide receptor-like 
1 (FPRL1) [32] and the P2X7 receptor [7]. This enables 
pleiotropic role of the peptide in infl ammation and tissue 
repair processes, infl uencing correct functioning of the 
respiratory tract. LL-37 stimulates angiogenesis [13], in-
duces proliferation of lung epithelial cells [26], accelerates 
wound closure of the airway epithelium [26], and provokes 
cytokine release (e.g. IL-8) and cell migration [13]. Human 
cells exposed to LL-37 can undergo necrosis [26]. 
Extensive clinical use of antibiotic drugs has led to a 
dramatic increase of the resistance of various microorgan-
isms, especially within the lung. As a result, development 
of new classes of antibiotics has become one of the priori-
ties for biomedical sciences and the pharmaceutical indus-
try [17]. Antimicrobial peptides and their synthetic deriva-
tives are seen as a potential alternative for currently used 
antibiotics. This is further encouraged by the improvement 
of wound healing caused by antimicrobial peptides. 
LPS AND LL-37: INVOLVEMENT IN 
PATHOGENESIS OF RESPIRATORY DISEASES
A variety of polysaccharides produced by Gram-nega-
tive bacteria play an important role in pathogenesis of 
many exogenous respiratory diseases, including organic 
dust toxic syndrome and chronic illnesses such as COPD, 
asthma or allergic alveolitis (hypersensitivity pneumoni-
tis). LPS adds also to the course of Gram-negative infec-
tions and its massive release can lead to life threatening 
pathology: endotoxic shock [25]. Endotoxins stimulate hu-
man organism immune system response and cause injury 
to the respiratory epithelia [19, 25] – which results in en-
hancing infl ammation and tissue repair. Millions of people 
working in agriculture and related industries (e.g. herb and 
wood processing facilities) are chronically exposed to LPS 
[8, 9, 22]. Apart from its mostly pathogenic role, moderate 
long-term exposure to LPS has been also described as a 
protective factor against lung cancer [14] and asthma in 
countryside children [27]. 
LPS, as a strong pro-infl ammatory stimulus, induces in 
respiratory airways expression of antimicrobial peptides, 
including LL-37, which is in turn a potent LPS-neutra-
lizing factor [5, 18]. By this activity LL-37 is protecting 
airways against LPS-derived activation of immune sys-
tem. It is also conceivable that the peptide LL-37, due to 
the wide spectrum and character of its biological func-
tions (including enhancing infl ammatory reaction, tissue 
remodeling processes and its antimicrobial and anti-LPS 
activities), also takes part in the pathogenesis of chronic 
infl ammatory diseases of the respiratory system, such as 
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COPD. As a result of this, LL-37 may exert both benefi cial 
and pathological effects during the development of chronic 
infl ammatory lung diseases. An ambivalent role of LL-37 
is possible, especially in the case of lung diseases caused 
by organic dust – in the presence of long-term and recur-
rent exposure to LPS – and lung injuries caused by inhaled 
organic dust particles. 
Xiao et al. [31] have observed higher levels of LL-37 
in the sputum of patients with COPD and reduced concen-
tration of LL-37 in asthma patients compared to healthy 
volunteers. This may suggest a role of LL-37 in the deve-
lopment of COPD and asthma. 
These data may indicate a versatile, complex interplay 
between endotoxin and the LPS-neutralizing, pleiotropic 
peptide LL-37 in pathogenic mechanisms of lung diseases. 
Potentially, the nature of these interactions differs depend-
ing on the kind (asthma/COPD) and character of disease 
– either chronic (COPD, asthma) – or acute (endotoxic 
shock, infectious exacerbations in chronic diseases, organic 
dust toxic syndrome). 
CONCLUSIONS 
LL-37 and its synthetic derivatives are under investi-
gation as therapeutic agents – pulmonary diseases are of 
high interest for such LL-37-based therapeutic strategies, 
which can potentially use combined anti-LPS, antimicro-
bial and wound healing features of the peptide [17]. Immu-
nostimulating effects of endotoxin are also in the scope of 
scientists´ interests due to its expected benefi cial effects if 
properly administered [6, 29, 11]. Thus, there is an impor-
tant need of further unraveling the role of LL-37, including 
especially LL-37/LPS interactions, in pulmonary patholo-
gies. This is highly requested in agricultural environment, 
where exposure to airborne LPS and diseases caused by 
organic dust are very common.
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